This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Open AccessArticle
Efficacy and Safety in a Real-World Study of the New Oral Formulation of Semaglutide in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus
by
María Marques Vidas
María Marques Vidas 1,2,*,
Paula López-Sánchez
Paula López-Sánchez 1
,
Paula Sánchez-Briales
Paula Sánchez-Briales 1,
María Victoria López Illazquez
María Victoria López Illazquez 1 and
Jose Portolés
Jose Portolés 1,2
1
Nephrology Department, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, 28222 Madrid, Spain
2
Medicine Department, Facultad de Medicina, Universidad Autónoma de Madrid, IDIPHISA, 28029 Madrid, Spain
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2024, 13(17), 5166; https://doi.org/10.3390/jcm13175166 (registering DOI)
Submission received: 3 July 2024
/
Revised: 12 August 2024
/
Accepted: 29 August 2024
/
Published: 30 August 2024
Abstract
Background/Objectives: GLP-1 receptor agonists (GLP-1RAs) have emerged as fundamental components in the treatment of type 2 diabetic patients (T2DM) with chronic kidney disease (CKD). The oral formulation represents a novel therapeutic tool but may affect drug efficacy. This study sought to compare the effectiveness of subcutaneous versus oral semaglutide formulations in patients with CKD. Methods: A retrospective study in a real-world setting compared type 2 diabetes and chronic kidney disease patients, initiating oral semaglutide treatment to a historically matched control group treated with subcutaneous semaglutide. The matching considered factors such as estimated glomerular filtration rate (eGFR), age, and sex. Results: Nineteen patients were included in both groups, with a mean age of 68.0. Seventy-two percent were males with a CKD-EPI eGFR of 49.9 mL/min/1.73 m2 and a median urine albumin-to-creatinine ratio of 12.7 mg/g. Of the study participants, 94% and 79% of patients were on the maximum semaglutide sbc vs. oral dose, while 5.3% and 15.8% were on the sbc vs. oral low dose. Oral semaglutide significantly reduced HbA1C and BMI, identical to the control group (−0.9 and −1.4, p > 0.05). Renal function parameters and blood pressure remained stable throughout the follow-up in both groups. The main side effect was digestive intolerance (affecting three patients in the oral group and two patients in the subcutaneous group, p = 0.6), although the treatment abandonment percentage was similar. Conclusions: The oral formulation of semaglutide demonstrated equivalent effectiveness in glucose control and body weight management in patients with T2DM and CKD, even with a higher proportion of patients receiving low to medium doses. Gastrointestinal side effects were comparable between both oral and subcutaneous formulations.
Share and Cite
MDPI and ACS Style
Marques Vidas, M.; López-Sánchez, P.; Sánchez-Briales, P.; López Illazquez, M.V.; Portolés, J.
Efficacy and Safety in a Real-World Study of the New Oral Formulation of Semaglutide in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus. J. Clin. Med. 2024, 13, 5166.
https://doi.org/10.3390/jcm13175166
AMA Style
Marques Vidas M, López-Sánchez P, Sánchez-Briales P, López Illazquez MV, Portolés J.
Efficacy and Safety in a Real-World Study of the New Oral Formulation of Semaglutide in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus. Journal of Clinical Medicine. 2024; 13(17):5166.
https://doi.org/10.3390/jcm13175166
Chicago/Turabian Style
Marques Vidas, María, Paula López-Sánchez, Paula Sánchez-Briales, María Victoria López Illazquez, and Jose Portolés.
2024. "Efficacy and Safety in a Real-World Study of the New Oral Formulation of Semaglutide in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus" Journal of Clinical Medicine 13, no. 17: 5166.
https://doi.org/10.3390/jcm13175166
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details
here.
Article Metrics
Article Access Statistics
For more information on the journal statistics, click
here.
Multiple requests from the same IP address are counted as one view.